Full bibliography

Ahlgren L. Ivarsson S. Johansson L. Mattsson S. Nosslin B. , 1985. Excretion of radionuclides in human breast milk after the administration of radiopharmaceuticals. J. Nucl. Med. 26, 1085–1090.

Anderson D.W. Richter C.W. Ficken V.J. , 1972. Use of thermoluminescent dosimeters for measurement of dose to the hands of nuclear medicine technicians. J. Nucl. Med. 13, 627–629.

Armbrecht J.J. Burton D.B. Schelbert H.R. , 1990. Validation of [1-¹¹C]acetate as a tracer for non-invasive assessment of oxidative metabolism with positron emission tomography in normal, ischemic, postischemic and hyperaemic canine myocardium. Circulation 81, 1594–1605.

ARSAC, 2006. Notes for Guidance on the Clinical Administration of Radiopharmaceuticals and Use of Sealed Radioactive Sources. Administration of Radioactive Substances Advisory Committee, Health Protection Agency, Chilton, UK.

Atkins H.L. Christman D.R. Fowler J.S. , 1972. Organic radiopharmaceuticals labeled with isotopes of short half-life. V. 18F-Labeled 5- and 6-Fluorotryptophan. J. Nucl. Med. 13, 713–719.

Atkins H.L. Cloutier R.J. Lathrop K.A. , 1975. Technetium-99m-sulfur colloid in various liver conditions. MIRD Dose Estimate Report No. 3. J. Nucl. Med. 16, 108A–108B.

Atkins H.L. Budinger T.F. Lebowitz E. , 1977. Thallium-201 for medical use. Part 3: Human distribution and physical imaging properties. J. Nucl. Med. 18, 133–140.

Aubert B. Guilabert N. Lamon A. , 2002. What protection against radiation for new protocols of internal radiotherapy by yttrium-90? Sixth European ALARA Network Workshop in Occupational Exposure Optimization in Medical Field and Radiophamaceutical Industry, pp. 44–49 (http://www.eu-alara.net/images/stories/pdf/program6/Session%20B/B_Aubert.pdf).

Bajc M. Palmer J. Ohlsson T. , 1994. Distribution and dosimetry of ¹¹¹In DTPA-D-phe-octreotide in man assessed by whole body scintigraphy. Acta Radiol. 35, 53–57.

Barthel H. Wiener M. Dannenberg C. Bettin S. Sattler B. Knapp W.H. , 1997. Age-specific cerebral perfusion in 4- to 15-year-old children: A high-resolution brain SPET study using ^99mTc-ECD. Eur. J. Nucl. Med. 24, 1245–1252.

Bartlett R.D. Lathrop K.A. Faulhaber P.F. Harper P.V. , 1984. Transfer of thallous ion to and from gastrointestinal sections. J. Nucl. Med. 25, P92.

Batchelor S. Baldock C. Webber D. , 1991a. Radiation dose to the hands of a radiopharmacist. J. Hosp. Pharm. 247 (Suppl.), 38–39.

Batchelor S. Penfold A. Huggins R. , 1991b. Radiation dose to the hands in nuclear medicine. Nucl. Med. Commun. 12, 439–444.

Berg G. Nyström E. Jacobsson L. , 1998. Radioiodine treatment of hyperthyroidism in a pregnant woman. J. Nucl. Med. 39, 357–361.

Bergmann R. Brust P. Kampf G. Coenen H.H. Stöcklin G. , 1995. Evaluation of radioselenium labeled selenomethionine, a potential tracer for brain protein synthesis by PET. Nucl. Med. Biol. 22, 475–481.

Berman M. , 1977. Kinetic Models for Absorbed Dose Calculation. Medical Internal Radiation Committee (MIRD) Pamphlet No. 12. Society of Nuclear Medicine, New York, NY.

Berridge M.S. Adler L.P. Rao P.S. , 1991. Radiation absorbed dose for O-15-butanol and O-15 water estimated by positron emission tomography. J. Nucl. Med. 32, 1043.

Berus D. Covens P. Buls N. , 2004. Extremity doses of workers in nuclear medicine: mapping hand doses in function of manipulation. Proceedings of the 11th International Congress of the IRPA, Madrid, 2004; 5f8 (http://irpa11.irpa.net/papers/papers.php).

Bingham D. Gardin I. Hoyes K.P. , 2000. The problem of Auger emitters for radiological protection. Radiat. Prot. Dosim. 92, 219–228.

Bischof Delaloye A. Delaloye B. , 1995. Radiolabelled monoclonal antibodies in tumour imaging and therapy: Out of fashion?. Eur. J. Nucl. Med. 22, 571–580.

Bjurman B. Ahlgren B. Mattsson S. , 1982. Radiation dose to staff handling 99mTc in hospitals. III International Symposium, Radiological Protection Advances in Theory and Practice, Inverness 6–11 June 1982. Proceedings, Vol. 2, pp. 588–593.

Booij J. Sokole E.B. Stabin M.G. Janssen A.G.M. de Bruin K. van Royen E.A. , 1998. Human biodistribution and dosimetry of [¹²³I]FP-CIT: a potent radioligand for imaging of dopamine transporters. Eur. J. Nucl. Med. 25, 24–30.

Booij J. Sokole E.B. Stabin M.G. Janssen A.G.M. de Bruin K. van Royen E.A. , 1998. Human biodistribution and dosimetry of [¹²³I]FP-CIT: a potent radioligand for imaging of dopamine transporters: erratum. Eur. J. Nucl. Med. 25, 458.

Bouchet L.G. Bolch W.E. Weber D.A. Atkins H.L. Poston J.W. Sr. , 1999. Radionuclide S-values in a revised dosimetric model of the adult head and brain. MIRD Pamphlet No. 15. J. Nucl. Med. 40, 62S–101S.

Bouchet L.G. Bolch W.E. Howell R.W. Rao D.V. , 2000. S values for radionuclides localized within the skeleton. J. Nucl. Med. 41, 189–212.

Boundy K.L. Barnden L.R. Rowe C.C. , 1995. Human dosimetry and biodistribution of iodine-123-iododexetimide: A SPECT imaging agent for cholinergic muscarinic neuroreceptors. J. Nucl. Med. 36, 1332–1338.

Boyes R.E. Cumming P. Martin W.R.W. McGeer E.G. , 1986. Determination of plasma [¹⁸F]-6-fluorodopa during positron emission tomography; elimination and metabolism in carbidopa treated subjects. Life Sci. 39, 2243–2252.

Brihaye C. Depresseux J.C. Comar D. , 1995. Radiation dosimetry for bolus administration of oxygen-15 water. J. Nucl. Med. 36, 651–656.

Britton K.E. Granowska M. , 1987. Radioimmunoscintigraphy in tumour identification. Cancer Surv. 6, 247–267.

Bronskill M.J. , 1983. Radiation dose estimates for interstitial radiocolloid lymphoscintigraphy. Semin. Nucl. Med. 13(1), 20–25.

Brown P.H. Krishnamurthy G.T. Bobba V.R. Kingston E. , 1981. Radiation-dose calculation for Tc-99m HIDA in health and disease. J. Nucl. Med. 22, 177–183.

Brown P.H. Krishnamurthy G.T. Bobba V.R. Kingston E. Turner F.E. , 1982. Radiation-dose calculation for five Tc-99m IDA hepatobiliary agents. J. Nucl. Med. 23, 1025–1030.

Brown W.D. Oakes T.R. DeJesus O.T. , 1998. Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatment. J. Nucl. Med. 39, 1884–1891.

Burns H.D. Dannals R.F. Langström B. , 1984. 3-N-[¹¹C]methylspiperone, a ligand binding to dopamine receptors: radiochemical synthesis and biodistribution studies in mice. J. Nucl. Med. 25, 1222–1227.

Casteels M. Foulon V. Mannaerts G.P. van Veldhoven P. , 2003. Alpha-oxidation of 3-methyl-substituted fatty acids and its thiamine dependence. Eur. J. Biochem. 270, 1619–1627.

Castronovo F.P. Jr. Stone H. Ulanski J. , 2000. Radioactivity in breast milk following ¹¹¹In-octreotide. Nucl. Med. Commun. 21, 695–699.

Caveliers V. Franken P.R. Florian F.L. Lou H. Knapp F.F. Jr. , 1998. Intra-individual comparison of 3(R)-BMIPP and 3(S)-BMIPP isomers in humans. J. Nucl. Med. 39, 1672–1675.

Chen C.T. Lathrop K.A. Harper P.V. , 1983. Quantitative measurement of long term in vivo thallium distribution in the human. J. Nucl. Med. 24, P50.

Chiesa C. de Sanctis V. Crippa F. , 1997. Radiation dose to technicians per nuclear medicine procedure: Comparison between technetium–99m, gallium-67 and iodine-131 radiotracers and fluorine-18 fluorodeoxyglucose. Eur. J. Nucl. Med. 24, 1380–1389.

Claessens R.A.M.J. Koenders E.B. Boerman O.C. , 1995. Dissociation of indium from indium-111-labelled diethylene triamine penta-acetic acid conjugated non-specific polyclonal human immunoglobulin G in inflammatory foci. Eur. J. Nucl. Med. 22, 212–219.

Clarke E.A. Brisco S.L. , 1986. Dispensing, injecting or imaging? A question of radiation doses. Nucl. Med. Commun. 7, 319.

Cloutier R.J. Watson E.E. Rohrer R.H. Smith E.M. , 1973. Calculating the radiation dose to an organ. J. Nucl. Med. 14, 53–55.

Cloutier R.J. Freeman L.M. McAfee J.G. , 1975. Summary of current radiation dose estimates to humans with various liver conditions from ¹⁹⁸Au colloidal gold. MIRD Dose Estimate Report No. 4. J. Nucl. Med. 16, 173–174.

Coenen H.H. Kling P. Stöcklin G. , 1989. Cerebral metabolism of 1-[2-¹⁸F]fluorotyrosine, a new PET tracer of protein synthesis. J. Nucl. Med. 30, 1367–1372.

Coffey J.L. Watson E.E. , 1979. Calculating doses from remaining body activity. A comparison of two methods. Med. Phys. 6, 307–308.

Comar D. Catron J.C. Maziere M. Marazanop C. , 1976. Labelling and metabolism of methionine-methyl-¹¹C. Eur. J. Nucl. Med. 1, 11–14.

Cottrall M.F. Taylor D.M. McElwain T.J. , 1973. Investigations of ¹⁸F-p-fluorophenylalanine for pancreas scanning. Br. J. Radiol. 46, 277–288.

Covens P. Berus D. Buls N. , 2007. Personal dose monitoring in hospitals: Global assessment, critical applications and future needs. Rad. Prot. Dosim. 124, 250–259.

Cremonesi M. Ferrari M. Paganelli G. , 2006. Radiation protection in radionuclide therapies with ⁹⁰Y-conjugates: risks and safety. Eur. J. Nuc. Med. Mol. Im. 33, 1321–1327.

Cronin B.F. , 2002. The technologist's perspective, in Valk P.E. Bailey D.L. Townsend D.W. (Eds.), Positron Emission Tomography; Basic Science and Clinical Practice. Springer-Verlag, London, pp. 777–791.

Cristy M. Eckerman K. , 1987. Specific Absorbed Fractions of Energy at Various Ages from Internal Photon Sources. Oak Ridge National Laboratory, Oak Ridge, TN.

De Geeter F. Caveliers V. Pansar I. Bossuyt A. Franken P.R. , 1998. Effect of oral glucose loading on the biodistribution of BMIPP in normal volunteers. J. Nucl. Med. 39, 1850–1856.

Delacroix D. Guerre J.P. Leblanc P. , 2002. Radionuclide and Radiation Protection Data Handbook. Rad. Prot. Dosim. 98(1). Nuclear Technology Publishing, Ashford.

Deloar H.M. Fujiwara T. Shidahara M. , 1998a. Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-D-glucose using whole-body positron emission tomography and magnetic resonance imaging. Eur. J. Nucl. Med. 25, 565–574.

Deloar H.M. Fujiwara T. Nakamura T. , 1998. Estimation of internal absorbed dose of 1-[methyl-¹¹C]-methionine using whole body positron emission tomography. Eur. J. Nucl. Med. 25, 629–633.

Deterding T.A. Votaw J.R. Wang C.K. , 2001. Biodistribution and radiation dosimetry of the dopamine transporter ligand [¹⁸F]FECNT. J. Nucl. Med. 42, 376–381.

Dhanse S. Martin C.J. Hilditch T.E. , 2000. A study of doses to the hands during dispensing of radiopharmaceuticals. Nucl. Med. Commun. 21, 511–519.

Dhawan V. Belakhlef A. Robeson W. , 1996. Bladder wall radiation dose in humans from fluorine-18-FDOPA. J. Nucl. Med. 37, 1850–1852.

Donadille L. Bouachri A.El. Lahaye T. , 2005. Feasibility study of an activity extremity dosimetry prototype. Radiat. Prot. Dosim. 115, 548–552.

Dudczak R. Schmoliner R. Angelberger P. Knapp F.F. Goodman M.M. , 1986. Structurally modified fatty acids: Clinical potential as tracers of metabolism. Eur. J. Nucl. Med. 12, S45–S48.

Eckerman K.F. Stabin M.G. , 2000. Electron absorbed fractions and dose conversion factors for marrow and bone by skeletal region. Health Phys. 78, 199–214.

Eichling J.O. Bergman S.R. Schwarz S.W. , 1997. Equivalent dose estimates in adults for intravenously administered O-15 water. Unpublished; personal communication through S. Schwarz.

Evans J.L. Mountford P.J. Herring A.N. Richardson M.A. , 1993. Secretion of radioactivity in breast milk following administration of ⁹⁹Tc^m-MAG3. Nucl. Med. Commun. 14, 108–111.

Eshima D. Fauconnier T. Eshima L. , 2000. Radiopharmaceuticals for lymphoscintigraphy; including dosimetry and radiation considerations. Semin. Nucl. Med. 30(1) 25–32.

Farde L. Hall H. Ehrin E. Sedvall G. , 1986. Quantitative analysis of D2 dopamine receptor binding in the living human brain. Science 231, 258–261.

Farde L. Suhara T. Nyberg S. , 1997. A PET study of [¹¹C]FLB 457 binding to extrastriatal D₂-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology 133, 394–404.

Feinendegen L.E. Neumann R.D. , 2004. Dosimetry and risk from low- versus high-LET radiation of Auger events and the role of nuclide carriers. Int. J. Radiat. Biol. 80, 813–822.

Fishman A.J. Khaw B.A. Strauss H.N. , 1989. Quo vadis radioimmune imaging. J. Nucl. Med. 20, 1911–1915.

Forssell Aronsson E. Fjälling M. Nilsson O. , 1995. Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide. J. Nucl. Med. 36, 7–12.

Forssell Aronsson E. Lanhede B. Fjälling M. , 1996. Pharmacokinetics and dosimetry of ¹¹¹In-DTPA-D-Phe-1-octreotide in patients with neuroendocrine tumours, in: Schlafke-Stelson A.T. Stabin M.G. Sparks R.B. (Eds.), Proceedings of the Sixth International Radiopharmaceutical Dosimetry Symposium. Oak Ridge Associated Universities, Oak Ridge, TN, pp. 643–655.

Freeman M.R. Kanwar N. Armstrong P.W. , 1986. The variability of thallium half life at rest as compared to exercise. J. Nucl. Med. 27, 997.

Frost J.J. Mayberg H.S. Sadzot B. , 1990. Comparison of [¹¹C]diprenorphine and [¹¹C]carfentanil binding to opiate receptors in humans by positron emission tomography. J. Cereb. Blood Flow Metab. 10, 484–492.

Gardin I. Faraggi M. Le Guludec D. Bok B. , 1999. Cell irradiation caused by diagnostic nuclear medicine procedures: Dose heterogeneity and biological consequences. Eur. J. Nucl. Med. 26, 1617–1626.

Gelfand M.J. Thomas S.R. Kereiakes J.G. , 1983. Absorbed radiation dose from routine imaging of the skeleton in children. Ann. Radiol. 26, 421–423.

Gemmell H.G. Staff R.T. 1998. Single-photon emission-computed tomography (SPECT) In: Practical Nuclear Medicine 2nd Edition, ed. Sharp P. F. Gemmell H. G. Smith F. W. , Oxford University press, Oxford, pp 13–24.

Gerson M.C. Lukes J. Deutsch E. , 1994. Comparison of technetium 99m Q12 and thallium 201 for detection of angiographically documented coronary artery disease in humans. J. Nucl. Cardiol. 1, 499–508.

Goddu S.M. Howell R.W. Rao D.V. , 1994. Cellular dosimetry: Absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J. Nucl. Med. 35, 303–316.

Goddu S.M. Howell R.W. Bouchet L.G. Bolch W.E. Rao D. , 1997. MIRD Cellular S Values. Society of Nuclear Medicine, Inc, Reston, VA.

Gössner W. Masse R. Stather J.W. , 2000. Cells at risk for dosimetric modelling relevant to bone tumour induction. Radiat. Prot. Dosim. 92, 209–213.

Groshar D. Slobodin G. Zuckerman E. , 2002. Quantitation of liver and spleen uptake of 99mTc-phytate colloid using SPECT: Detection of liver cirrhosis. J. Nucl. Med. 43, 312–317.

Gründer G. Siessmeier T. Lange-Asschenfeldt C. , 2001. [¹⁸F]Fluoroethylflumaazenil: a novel tracer for PET imaging of human benzodiazepine receptors. Eur. J. Nucl. Med. 28, 1463–1470.

Gründer G. Siessmeier T. Piel M. , 2003. Quantification of D₂-like dopamine receptors in the human brain with [¹⁸F]-desmethoxyfallypride. J. Nucl. Med. 44, 109–116.

Guillet B. Quentin P. Waultier S. , 2005. Technologist radiation exposure in routine clinical practice with ¹⁸F FDG PET. J. Nucl. Med. Technol. 33, 175–179.

Gunnarsson M. Stenström K. Leide-Svegborn S. , 2003. Biokinetics and radiation dosimetry for patients undergoing a glycerol tri[1-¹⁴C]oleate fat malabsorption breath test. Appl. Radiat. Isot. 58, 517–526.

Gupta S.M. Herrera N. Spencer R.P. , 1981. Testicular-scrotal content of ²⁰¹Tl and ⁶⁷Ga after intravenous administration. Int. J. Nucl. Med. Biol. 8, 211–213.

Guy M.J. Greaves C.D. Morton R.J. , 2005. Development of a combined audiovisual and extremity dose monitoring software tool for use in nuclear medicine. Nucl. Med. Comm. 26, 1147–1153.

Harding L.K. Hesslewood S. Ghose S.K. , 1985. The value of syringe shields in a nuclear medicine department. Nucl. Med. Commun. 6, 449–454.

Harding L.K. Mostafa A.B. Thomson W.H. , 1990. Staff radiation doses associated with medicine procedures — a review of some recent measurements. Nucl. Med. Commun. 11, 272–277.

Harvey J. Firnau G. Garnett E.S. , 1985. Estimation of the radiation dose in man due to 6-[¹⁸F]fluoro-L-dopa. J. Nucl. Med. 26, 931–935.

Hastings D.L. Hillel P.G. Jeans S.P. , 1997. Assessment of finger doses received by staff while preparing and injecting radiopharmaceuticals. Nucl. Med. Commun. 18, 785–790.

Hays M.T. Segall G.M. , 1999. A mathematical model for the distribution of fluorodeoxyglucose in humans. J. Nucl. Med. 40, 1358–1366.

Hays M.T. Watson E.E. Thomas S.R. Stabin M. , 2002. Radiation absorbed dose estimates from ¹⁸F-FDG. MIRD Dose Estimate Report No. 19. J. Nucl. Med. 43, 210–214.

Heiss W.D. Wienhard K. Wagner R. , 1996. F-DOPA as an amino acid tracer to detect brain tumors. J Nucl. Med. 37, 1180–1182.

Herscovitch P. Carson R.E. Stabin M. , 1993. A new kinetic approach to estimate the radiation dosimetry of flow-based radiotracers. J. Nucl. Med. 34, 155P.

Herscovitch P. Schmall B. Doudet D. Carson R. Eckelman W. , 1997. Biodistribution and radiation dose estimates for [¹¹-C]raclopride (abstract). J. Nucl. Med. 5 (Suppl.), 224.

Herzog H. Spohr G. Notohamiprodjo G. Feinendegen L.E. , 1987. Absolute quantification of pharmacokinetic distribution of RES colloids in individuals with normal liver function. Nucl. Med. Commun. 8, 157–175.

Higley B. Smith F.W. Smith T. , 1993. Technetium-99m-1,2-bis[bis(2-ethoxyethyl) phosphino]ethane: Human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J. Nucl. Med. 34, 30–38.

Hofer K.G. , 1996. Biophysical aspects of Auger processes. A review. Acta Oncol. 35, 789–796.

van den Hoff J. Burchert W. Wolpers H.G. Meyer G.J. Hundeshagen H. , 1996. A kinetic model for cardiac PET with [1-¹¹C]acetate. J. Nucl. Med. 37, 521–529.

Hoffman J.M. Melega W.P. Hawk T.C. , 1992. The effects of carbidopa administration of 6-[¹⁸F]fluoro-L-DOPA kinetics in positron emission tomography. J. Nucl. Med. 33, 1472–1477.

Holman B.L. Hellman R.S. Goldsmith S.J. , 1989. Biodistribution, dosimetry and clinical evaluation of technetium-99m ethyl cysteinate dimer in normal subjects and in patients with chronic cerebral infarction. J. Nucl. Med. 30, 1018–1024.

Hosain P. Hosain F. , 1981. Revision of gonadal radiation dose to man from thallium-201, in: Proceedings of the Third International Radiopharmaceutical Dosimetry Symposium, Oak Ridge 1980 (FDA 81-8166) Oak Ridge National Laboratories, Oak Ridge, TN, pp. 333–345.

Houle S. DaSilva J.N. Wilson A.A. , 2000a. Imaging the 5-HT_1A receptors with PET: WAY-100635 and analogues. Nucl. Med. Biol. 27, 463–466.

Houle S. Ginovart N. Hussey D. Meyer J.H. Wilson A.A. , 2000b. Imaging the serotonin transporter system with positron emission tomography: Initial human studies with [¹¹C]DAPP and [¹¹C]DASB. Eur. J. Nucl. Med. 27, 1719–1722.

Husak V. Ptacek J. Drymlova J. , 2007. Radiation dose to the hands of nuclear medicine staff preparing radiopharmaceuticals with gamma emitters including positron radionuclide 18F. Česka Radiologie 61, 80–84.

IAEA, 2006. Quality Assurance for Radioactivity Measurement in Nuclear Medicine. Technical Report Series No. 454. International Atomic Energy Agency, Vienna.

Inoue T. Tomiyoshi K. Higuichi T. , 1996. Biodistribution studies on 1–3-[fluorine-18]fluoro-α-methyl tyrosine: A potential tumor-detecting agent. J. Nucl. Med. 39, 663–667.

ICRP, 1971. Protection of the Patient in Radionuclide Investigations. ICRP Publication 17. Pergamon Press, Oxford.

ICRP, 1973. Alkaline Earth Metabolism in Adult Man. ICRP Publication 20. Pergamon Press, Oxford.

ICRP, 1975. Report of the Task Group on Reference Man. ICRP Publication 23. Pergamon Press, Oxford.

ICRP, 1977. Recommendations of the International Commission on Radiological Protection. ICRP Publication 26. Ann. ICRP 1(3).

ICRP, 1979. Limits for intakes of radionuclides by workers. ICRP Publication 30, Part 1. Ann. ICRP 2(3/4).

ICRP, 1980. Limits for intakes of radionuclides by workers. ICRP Publication 30, Part 2. Ann. ICRP 4(3/4).

ICRP, 1981. Limits for intakes of radionuclides by workers. ICRP Publication 30, Part 3. Ann. ICRP 6(2/3).

ICRP, 1987. Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53. Ann. ICRP 18(1–4).

ICRP, 1991a. 1990 Recommendations of the International Commission on Radiological Protection. ICRP Publication 60. Ann. ICRP 21(1–3).

ICRP, 1991b. Radiation dose to patients from radiopharmaceuticals. Addendum 1 to ICRP Publication 53. ICRP Publication 62. Ann. ICRP 22(3).

ICRP, 1993. Age-dependent doses to members of the public from intake of radionuclides. Part 2: Ingestion dose coefficients. ICRP Publication 67. Ann. ICRP 23(3/4).

ICRP, 1994. Dose coefficients for intake of radionuclides by workers. ICRP Publication 68. Ann. ICRP 24(4).

ICRP, 1996. Age-dependent doses to members of the public from intake of radionuclides. Part 5. ICRP Publication 72. Ann. ICRP 26(1).

ICRP, 1998. Radiation dose to patients from radiopharmaceuticals. Addendum 2 to ICRP Publication 53. ICRP Publication 80. Ann. ICRP 28(3).

ICRP, 2001a. Doses to the embryo and fetus from intake of radionuclides by the mother. ICRP Publication 88. Ann. ICRP 31(1–3).

ICRP, 2001b. Radiation dose to patients from radiopharmaceuticals. Addendum 4 to ICRP Publication 53.

ICRP, 2002. Basic anatomical and physiological data for use in radiological protection: Reference values. ICRP Publication 89. Ann. ICRP 31(3/4).

ICRP, 2003. Relative biological effectiveness (RBE), quality factor (Q) and radiation weighting factor (w_R). ICRP Publication 92. Ann. ICRP 33(4).

ICRP, 2004. Doses to infants from ingestion of radionuclides in mothers' milk. ICRP Publication 95. Ann. ICRP 34(3/4).

ICRP, 2006. Human alimentary tract model for radiological protection. ICRP Publication 100. Ann. ICRP 35(1/2).

ICRP, 2007. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP Publication 103. Ann. ICRP 37(2–4).

ICRU, 1979. Methods of Assessment of Absorbed Dose in Clinical Use of Radionuclides. ICRU Report 32. International Commission on Radiation Units and Measurements, Bethesda, MD.

ICRU, 2002. Absorbed-dose specification in nuclear medicine. ICRU Report 67. J. ICRU 2, 1–110.

Iyo M. Namba H. Fukushi K. , 1997. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 349, 1805–1809.

Jankowski J. Olszewski J. Kluska K. , 2003. Distribution of equivalent doses to skin of the hands of nuclear medicine personnel. Radiat. Prot. Dosim. 106, 177–180.

Johansson L. Mattsson S. Nosslin B. Leide-Svegborn S. , 1992. Effective dose from radiopharmaceuticals. Eur. J. Nucl. Med. 19, 933–938.

Johansson L. , 1996. Absorbed dose in the salivary glands from technetium-99m labeled radiopharmaceuticals, in: Schlafke-Stelson A Stabin M.G. Sparks R.B. (Eds.), Sixth International Radiopharmaceutical Dosimetry Symposium, Gatlinburg, TN. Oak Ridge Institute for Science and Education, pp. 513–521.

Johnston R.E. Mukherji S.K. Perry R.J. Stabin M.G. , 1996. Radiation dose from breastfeeding following administration of thallium-201. J. Nucl. Med. 37, 2079–2082.

Jönsson L. Ljungberg M. Strand S.E. , 2005. Evaluation of accuracy in activity calculations for the conjugate view method from Monte Carlo simulated scintillation camera images using experimental data in an anthropomorphic phantom. J. Nucl. Med. 46, 1679–1686.

Kassis A.M. , 2004. The amazing world of Auger electrons. Int. J. Radiat. Biol. 80, 789–903.

Kaul A. Krauss O. Petrausch G. , 1985. Strahlenexposition durch Tc-99m-Methylendiphosphonat — lokale Dosisverteilung in Wachstum zonen des kindlichen Skelett und Organdosen, in: Poretti G. (Ed.), Medizinische Physik. Deutsche Gesellschaft für medizinische Physik, Bern.

Kauppinen T.A. Bergström K.A. Heikman P. Hiltunen J. Ahonen A.K. , 2003. Biodistribution and radiation dosimetry of [¹²³I]ADAM in healthy human subjects: preliminary results. Eur. J. Nucl. Med. 30, 132–136.

Kim S. Wagner H.N. Jr. Villemagne V.L. , 1997. Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual detector system. J. Nucl. Med. 38, 1726–1731.

Knapp F.F. Jr. Ambrose K.R. Goodman M.M. , 1986. New radioiodinated methyl-branched fatty acids for cardiac studies. Eur. J. Nucl. Med. 12 (Suppl.), S39–S44.

Knapp F.F. Jr. Franken P. Kropp J. , 1995a. Cardiac SPECT with iodine-123-labeled fatty acids: Evaluation of myocardial viability with BMIPP. J. Nucl. Med. 36, 1022–1030.

Knapp F.F. Jr. Kropp J. , 1995b. Iodine-123-labelled fatty acids for myocardial single-photon emission tomography: Current status and future perspectives. Eur. J. Nucl. Med. 22, 361–381.

Koback R. Plato P. , 1985. Influence of dosemeter positioning on reported doses to the upper extremities. Radiat. Prot. Dosim. 11, 257–262.

Koizumi M. Endo K. Watanabe Y. , 1989. Pharmacokinetics of internally labeled monoclonal antibodies as a gold standard: Comparison of biodistribution of 75Se-, 111In-, and 125I-labeled monoclonal antibodies in osteogenic sarcoma xenografts in nude mice. Cancer Res. 49, 1752–1757.

Krahwinkel W. Herzog H. Feinendegen L.E. , 1988. Pharmacokinetics of thallium-201 in normal individuals after routine myocardial scintigraphy. J. Nucl. Med. 29, 1582–1586.

Krenning E.P. Bakker W.H. Kooij P.P.M. , 1992. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: Metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J. Nucl. Med. 33, 652–658.

Krenning E.P. Kwekkeboom D.J. Bakker W.H. , 1993. Somatostatin receptor scintigraphy with (¹¹¹In-DTPA-D-Phe¹)- and (¹²³I-Tyr³)-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 20, 716–731.

Kuikka J.T. Bergström K.A. Ahonen A. Länsimies E. , 1994. The dosimetry of iodine-123 labelled 2β-carbomethoxy-3β-(4-iodophenyl)tropane. Eur. J. Nucl. Med. 21, 53–56.

Laffont S. Deuvillers A. Garin E. , 2001. Radiation protection and radiation dose to technicians and patient during PET study (18FDG). Medecine Nucleaire 25, 395–400.

Leggett R.W. Williams L.R. , 1991. Suggested reference values for regional blood volumes in humans. Health Phys., 139–154.

Leggett R.W. Williams L.R. , 1995. A proposed blood circulation model for reference man. Health Phys. 69, 187–201.

Leide-Svegborn S. Nosslin B. Mattsson S. , 1996. Biokinetics and dosimetry of ¹¹¹In-DTPA-D-Phe-1-octreotide in patients, in: Schlafke-Stelson A.T. Stabin M.G. Sparks R.B. (Eds.), Proceedings of the Sixth International Radiopharmaceutical Dosimetry Symposium. Oak Ridge Associated Universities, Oak Ridge, TN, pp. 631–642.

Léveillé J. Demonceau G. Walovitch R.C. , 1992. Intrasubject comparison between technetium-99m-ECD and technetium-99m-HMPAO in healthy human subjects. J. Nucl. Med. 33, 480–484.

Liemann H. Will E. Beuthien-Baumann B. , 2000. Investigations of radiation exposure of the medical personnel during F-18 FDG PRT studies. Nuklear Medizin 39, 77–81, [in German].

Liepe K. Andreeff M. Wunderlich G. , 2005. Radiation protection in radiosynovectomy of the knee. Health Phys. 89, 151–154.

Liniecki J. , 1998. Private communication. Department of Nuclear Medicine. Medical University of Lodz, Lodz.

Loevinger R. Berman M. , 1968. A schema for absorbed-dose calculations for biologically distributed radionuclides. MIRD Pamphlet No. 1. J. Nucl. Med. 9 (Suppl. 1), 7–14.

Loevinger R. Budinger T.F. Watson E.E. , 1991. MIRD Primer for Absorbed Dose Calculations. Revised edition. Society of Nuclear Medicine, New York, NY.

Lu E. Meyer E. Kuwabara H. Ma Y. Shiraishi M. Evans A.C. , 1995. Reduction of radiation absorbed dose in F-18-DOPA PET studies by hydration-induced voiding. J. Nucl. Med. 36 (Suppl.), 98P.

Luxen A. Guillaume M. Melega W.P. Pike V.W. Solin O. Wagner R. , 1992. Production of 6[¹⁸F]fluoro-L-DOPA and its metabolism in vivo — a critical review. Nucl. Med. Biol. 19, 149–158.

Machulla H.J. Marsmann M. Dutschka K. , 1980. Biochemical concept and synthesis of a radioiodinated phenyl fatty acid for in vivo metabolic studies of the myocardium. Eur. J. Nucl. Med. 5, 171–173.

Mackenzie A. , 1997. Reduction of extremity dose in the radiopharmacy. Nucl. Med. Commun. 18, 578–581.

Martin C.J. Whitby M. , 2003. Application of ALARP to extremity doses for hospital workers. J. Radiol. Prot. 23, 405–421.

McClain D.A. Hug C.C. Jr. , 1980. Intravenous fentanyl kinetics. Clin. Pharmacol. Ther. 28, 106–114.

McCauley E. Mackie A. , 2002. Breast milk activity during early lactation following maternal ⁹⁹Tc^m macroaggregated albumin lung perfusion scan. Br. J. Radiol. 75, 464–466.

Meija A.A. Nakamura T. Masatoshi I. Hatazawa J. Mazaki M. Watanuki S. , 1991. Estimation of absorbed doses in humans due to intraveneous administration of fluorine-18-fluorodeoxyglucose in PET studies. J. Nucl. Med. 32, 699–706.

Melega W.P. Hoffman J.M. Luxen A. Nissenson C.H.K. Phelps M.E. Barrio J.P. , 1990. The effects of carbidopa on the metabolism of 6-[¹⁸F]fluoro-L-dopa in rats, monkeys and humans. Life Sci. 47, 149–157.

Meyer G.-J. Waters S.L. Coenen H.H. Luxen A. Maziere B. Långström B. , 1995. PET radiopharmaceuticals in Europe: Current use and data relevant for the formulation of summaries of product characteristics (SPCs). Eur. J. Nucl. Med. 22, 1420–1432.

Mielcarek J. Barth I. , 2002. Occupational beta radiation exposure during radiosynoviorthesis. Sixth European ALARA Network Workshop in Occupational Exposure Optimization in Medical Field and Radiophamaceutical Industry, pp. 43–46 (http://www.eu-alara.net/images/stories/pdf/program6/Session%20B/I_Barth.pdf).

Mitterhauser M. Wadsak W. Wabnegger L. , 2004. Biological evaluation of 2′-[¹⁸F]fluoroflumazenil ([¹⁸F]FFMZ): a potential GABA receptor ligand for PET. Nucl. Med. Biol. 31, 291–295.

Montgomery A. Martin C.J. Anstee D. , 1997. Application of a gamma extremity monitoring system in a radiopharmaceutical dispensary. Nucl. Med. Commun. 18, 673–679.

Montgomery A. Anstee D.E. Martin C.J. , 1999. Reduction in finger dose for radiopharmaceutical dispensing afforded by a syringe shield and an automatic dose dispenser. Nucl. Med. Commun. 20, 189–194.

Mountford P.J. Coakley A.J. , 1989. A review of the secretion of radioactivity in human breast milk: Data, quantitative analysis and recommendations. Nucl. Med. Commun. 10, 15–27.

Mozley P.D. Stubbs J.T. Kim H-J. , 1995. Dosimetry of a D2/D3 dopamine receptor antagonist that can be used with PET or SPECT. J. Nucl. Med. 36, 1322–1331.

Mozley P.D. Stubbs J.T. Kim H-J. , 1996. Dosimetry of an iodine-123-labeled tropane to image dopamine transporters. J. Nucl. Med. 37, 151–159.

Mulholland G.K. Kilbourn M.R. Sherman P. , 1995. Synthesis, in vivo biodistribution and dosimetry of [¹¹C]N-methylpiperidyl benzilate ([¹¹C]NMPB), a muscarinic acetylcholine receptor antagonist. Nucl. Med. Biol. 22, 13–17.

NCRP, 1982. Nuclear Medicine — Factors Influencing the Choice and Use of Radionuclides in Diagnosis and Therapy. NCRP Report No. 70. National Council on Radiation Protection and Measurements, Bethesda, MD.

NCRP, 1985. General Concepts for the Dosimetry of Internally Deposited Radionuclides. NCRP Report No. 84. National Council on Radiation Protection and Measurements, Bethesda, MD.

Neil C.M. , 1969. The question of radiation exposure to the hand from handling 99mTc. J. Nucl. Med. 10, 732–734.

Nettleton J.S. Lawson R.S. Prescott M.C. Morris I.D. , 2004. Uptake, localization, and dosimetry of ¹¹¹In and ²⁰¹Tl in human testes. J. Nucl. Med. 45, 138–146.

Norrgren K. Svegborn S.L. Areberg J. Mattsson S. , 2003. Accuracy of the quantification of organ acticity from planar gamma camera images. Cancer Biother. Radiopharm, 18.

Nosslin B. Johansson L. Leide-Svegborn S. Liniecki J. Mattsson S. Taylor D. , 2003. A generic model for 11C-labelled radiopharmaceuticals for imaging receptors in the human brain. Rad. Prot. Dosim. 105, 587–591.

Olsson H. Halldin C. Swahn G. Farde L. , 1999. Quantification of [¹¹C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. J. Cereb. Blood Flow Metab. 19, 1164–1173.

Osman S. Lundkvist C. Pike V.W. , 1996. Characterization of the radioactive metabolites of the 5-HT_1A receptor radioligand, [O-methy-¹¹C]WAY-100635, in monkey and human plasma by HPLC: comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET. Nucl. Med. Biol. 23, 627–634.

Pappata S. Samson Y. Chavoix C. Prenant C. Mazière M. Baron J.C. , 1988. Regional specific binding of [¹¹C]RO 15 1788 to central type benzodiazepine receptors in human brain: quantitative evaluation by PET. J. Cereb. Blood Flow Metab. 8, 304–313.

Paul G.S. Sharma S.K. Rath G.K. , 2006. Finger doses for staff handling radiopharmaceuticals in nuclear medicine. J. Nucl. Med. Technol. 34, 169–173.

Pauwels T. Dethy S. Goldman S. Monclus M. Luxen A. , 1994. Effect of catechol-O-methyl transferase inhibition on peripheral and central metabolism of 6-[¹⁸F]fluoro-L-DOPA. Eur. J. Pharmacol. 257, 53–58.

Persson A. Pauli S. Swahn C.G. Halldin C. Sedvall G. , 1989. Cerebral uptake of ¹¹C-Ro 15 1788 and its acid metabolite ¹¹C-Ro 15 3890: PET study in human volunteers. Human Psychopharmacol. 4, 215–220.

Pike V.W. McCarron J.A. Hume S.P. , 1995. Preclinical development of a radioligand for studies of central 5-HT1A receptors in vivo — [¹¹C]WAY-100635. Med. Chem. Res. 5, 208–227.

Rao D.V. Shepstone B.J. Wilkins H.B. Howell R.W. , 1995. Kinetics and dosimetry of thallium-201 in human testes. J. Nucl. Med. 36, 607–609.

Reske S.N. Biersack H.J. Lackner K. , 1982. Assessment of regional myocardial uptake and metabolism of omega-(p-123I-phenyl) pentadecanoic acid with serial single-photon emission tomography. Nuklearmedizin 21, 249–253.

Reske S.N. , 1985. 123I-phenylpentadecanoic acid as a tracer of cardiac free fatty acid metabolism. Experimental and clinical results. Eur. Heart J. 6 (Suppl. B), 39–47.

Rimpler A. Barth I. Senftleben S. , 2007. Beta radiation exposure of staff during therapies with Y-90 labeled substances. Beta-Days in Capri (Italy), 20–22 Sept. 2007 (http://www.uznuclear.rug.ac.be/betadayscapri/).

Rimpler A. Barth I. , 2007. Beta radiation exposure of medical staff and implications for extremity dose monitoring. Rad. Prot. Dosim. 125, 335–339.

Roedler H.D. , 1980. Accuracy of Internal Dose Calculations with Special Consideration of Radiopharmaceutical Biokinetics. Third International Radiopharmaceutical Dosimetry Symposium, Oak Ridge, TN. HHS Publication (FDA 81-8166). Department of Health and Human Welfare, Bureau of Radiological Health, Rockville, MD.

Roedler H.D. Kaul A. , 1976. Dose to Target Organs from Remaining Body Activity: Results of the Formally Exact and Approximate Solution. Radiopharmaceutical Dosimetry Symposium, Oak Ridge, TN. HEW Publication (FDA 76-8044). pp. 155–163.

Roedler H.D. Kaul A. Hine G.J. , 1978. Internal Radiation Dose in Diagnostic Nuclear Medicine. Hoffman, Berlin.

Rose M.R. Prescott M.C. Herman K.J. , 1990. Excretion of iodine-123-hippuran, technetium-99m-red blood cells, and technetium-99m-macroaggregated albumin into breast milk. J. Nucl. Med. 31, 978–984.

Rossetti C. Vanoli G. Paganelli G. , 1994. Human biodistribution, dosimetry and clinical use of technetium (III)-99m-Q12. J. Nucl. Med. 35, 1571–1580.

Rubow S. Klopper J. Wasserman H. Baard B. van Niekerk M. , 1994. The excretion of radiopharmaceuticals in human breast milk: Additional data and dosimetry. Eur. J. Nucl. Med. 21, 144–153.

Russell J.R. Stabin M.G. Sparks R.B. Watson E.E. , 1997. Radiation absorbed dose to the embryo/fetus from radiopharmaceuticals. J. Nucl. Med. 73, 756–769.

Ryan J. Cooper M. Loberg M. Harvey E. Sikorski S. , 1977. Technetium-99m-labelled N-(2,6-dimethylphenyl carbamoylmethyl)-iminodiacetic acid (Tc99mHIDA): A new radiopharmaceutical for hepatobiliary imaging studies. J. Nucl. Med. 18, 997–1004.

Samson G. Wackers F.J.Th. Becker A.E. , 1978. Distribution of thallium-201 in man, in: Oeff K Schmidt H.A.E. (Eds.), Nuklearmedizin und biokybernetik, Vol. 1. Medico-informationsdienste, Berlin, pp. 385–389.

Schmidt D. Langen K-J. Herzog H. , 1997. Whole-body kinetics and dosimetry of 1–3-[¹²³I]iodo-α-methyltyrosine. Eur. J. Nucl. Med. 24, 1162–1166.

Shleien B. Slaback L.A.S. Jr. Birky B.K. , 1998. Handbook of Health Physics and Radiological Health. Williams and Wilkins, Baltimore, MD.

Shoup T.M. Olson J. Hoffman J.M. , 1999. Synthesis and evaluation of [¹⁸F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumours. J. Nucl. Med. 40, 331–338.

Shreve P. Chiao P.C. Humes H.D. Schwaiger M. Gross M.D. , 1995. Carbon-11-acetate PET imaging in renal disease. J. Nucl. Med. 36, 1595–1601.

Shreve P.D. Gross M.D. , 1997. Imaging of the pancreas and related diseases with PET carbon-11-acetate. J. Nucl. Med. 38, 1305–1310.

Sloof G.W. Visser F.C. van Lingen A. , 1997. Evaluation of heart-to-organ ratios of 123I-BMIPP and the dimethyl-substituted 123I-DMIPP fatty acid analogue in humans. Nucl. Med. Commun. 18, 1065–1070.

Smith T. Veall N. Wootton R. , 1982. Bladder wall dose from administered radiopharmaceuticals: The effect of variation in urine flow rate, voiding interval and initial bladder content. Radiat. Prot. Dosim. 2, 183–189.

Smith T. Lahiri A. Gemmell H.G. , 1992. Dosimetry of ^99mTc-P53, a new myocardial perfusion imaging agent, in: Schlafke-Stelson A Watson E.E. (Eds.), Fifth International Radiopharmaceutical Dosimetry Symposium. CONF-910529. Oak Ridge Associated Universities, Oak Ridge, TN, pp. 467–481.

Smith T. Tong C. Lammertsma A.A. , 1994. Dosimetry of intravenously administered oxygen-15 labelled water in man: A model based on experimental human data from 21 subjects. Eur. J. Nucl. Med. 21, 1126–1134.

Snyder W.S. Ford M.R. Warner G.G. Fisher H.R. Jr , 1969. Estimates of absorbed fractions for monoenergetic photon sources uniformly distributed in various organs of a heterogeneous phantom. MIRD Pamphlet No. 5. J. Nucl. Med. 10 (Suppl. 3).

Snyder W.S. Ford M.R. Warner G.G. Watson S.B. , 1975. “S” Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs. MIRD Pamphlet No. 11. Society of Nuclear Medicine, New York, NY.

Snyder W.S. Ford M.R. , 1976. Estimation of doses to the urinary bladder and to the gonads, in: Cloutier R.J. (Eds.), Radiopharmaceutical Dosimetry Symposium, Oak Ridge, TN. HEW Publication (FDA 76-8044). Department of Health, Education and Welfare, Bureau of Radiological Health, Rockville, MD, pp. 313–349.

Snyder W.S. Ford M.R. Warner G.G. , 1978. Estimates of Specific Absorbed Fractions for Photon Sources Uniformly Distributed in Various Organs of a Heterogeneous Phantom. Medical Internal Radiation Dose Committee (NM/MIRD) Pamphlet No. 5, revised. Society of Nuclear Medicine, New York, NY.

Stabin M.G. , 1996. MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine. J. Nucl. Med. 37, 538–546.

Stabin M.G. Kooij P.P. Bakker W.H. , 1997. Radiation dosimetry for indium-111-pentetreotide. J. Nucl. Med. 38, 1919–1922.

Stabin M.G. Breitz H.B. , 2000. Breast milk excretion of radiopharmaceuticals: Mechanisms, findings, and radiation dosimetry. J. Nucl. Med. 41, 863–873.

Stabin M.G. Siegel J.A. , 2003. Physical models and dose factors for use in internal dose assessment. Health Phys. 83, 294–310.

Stabin M.G. Sparks R.B. Crowe E. , 2005. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J. Nucl. Med. 46, 1023–1027.

Stenhouse M.J. Baxter M.S. , 1977. Bomb ¹⁴C as a biological tracer. Nature (Lond.) 267, 828–832.

Stenström K. Leide-Svegborn S. Erlandsson B. , 1996. Application of accelerator mass spectrometry (AMS) for high-sensitivity measurements of ¹⁴CO₂ in long-term studies of fat metabolism. Appl. Radiat. Isot. 47, 417–422.

Stepanek J. Larsson B. Weinreich R. , 1996. Auger-electron spectra of radionuclides for therapy and diagnostics. Acta Oncol. 35, 863–868.

Stuardo E. , 1990. Hand dose levels in Chilean nuclear medicine laboratories. Radiat. Prot. Dosim. 34, 127–130.

Sun K.T. Chen K. Huang S-C. , 1997. Compartment model for measuring myocardial oxygen consumption using [1-¹¹C]acetate. J. Nucl. Med. 38, 459–466.

Surma M.J. Wiewiora J. Liniecki J. , 1994. Usefulness of ^99mTc-N,N'-ethylene-1-dicysteine complex for dynamic kidney investigations. Nucl. Med. Comm. 15, 628–635.

Surma M.J. , 1998a. Verification of ^99mTc-ethylenedicysteine (^99mTc-EC) distribution model in the organism. Nucl. Med. Rev. 1, 29–32.

Surma M.J. , 1998b. ^99mTc-Ethylenedicysteine (^99mTc-EC) renal clearance determination error for the multiple- and single-sample methods. Nucl. Med. Rev. 1, 33–40.

Syed I.B. , 1976. Dosimetry of indium-113m radiopharmaceuticals with special attention to the urinary bladder, in: Cloutier R.J. (Eds.), Radiopharmaceutical Dosimetry Symposium, Oak Ridge, TN. HEW Publication (FDA 76-8044). Department of Health, Education and Welfare, Bureau of Radiological Health, Rockville, MD, pp. 360–369.

Szabo Z. Scheffel U. Mathews W.B. , 1999. Kinetic analysis of [¹¹C]McN5652: a serotonin transporter radioligand. J. Cereb. Blood Flow Metab. 19, 967–981.

Taavitsainen M. Riihimäki E. Tähti E. , 1980. Body disappearance and liver mean transit time of 99m-Tc-diethyl-IDA. Eur. J. Nucl. Med. 5, 147–150.

Taillefer R. Edell S. Innes G. Lister-James J. , 2000. Acute thromboscintigraphy with (99m)Tc-apcitide: Results of the phase 3 multicenter clinical trial comparing 99mTc-apcitide scintigraphy with contrast venography for imaging acute DVT. Multicenter trial investigators. J. Nucl. Med. 41, 1214–1223.

Tamaki N. Morita K. Kuge Y. Tsukamoto E. , 2000. The role of fatty acids in cardiac imaging. J. Nucl. Med. 41, 1525–1534.

Tanaka N. Fukushi K. Shinotoh H. , 2001. Positron emission tomographic measurement of brain acetylcholinesterase activity using N-[¹¹C]methylpiperidin-4-yl acetate without arterial blood sampling: methodology of shape analysis and its diagnostic power for Alzheimer's disease. J. Cereb. Blood Flow Metab. 21, 295–306.

Tandon P. Venkatesh M. Bhatt B.C. , 2007. Extremity dosimetry for radiation workers handling unsealed radionuclides in nuclear medicine departments in India. Health Phys. 92, 112–118.

Taylor D.M. , 2000a. Unpublished assessments.

Taylor D.M. , 2000b. Generic models for radionuclide dosimetry: ¹¹C, ¹⁸F or ⁷⁵Se-labelled amino acids. Appl. Radiat. Isot. 52, 911–922.

Taylor D.M. , 2000c. Subcellular distribution of gallium-67 and other Auger-emitting radionuclides in human and animal tissues. Radiat. Prot. Dosim. 92, 229–231.

Taylor D.M. Cottrall M.F. , 1973. Evaluation of amino acids labelled with ¹⁸F for pancreas scanning, in: Radiopharmaceuticals and Labelled Compounds, Vol. I. IAEA, Vienna, pp. 441–443.

Thomas S.R. Stabin M.G. Chen C.-T. Samaratunga R.C. , 1999. A dynamic urinary bladder model for radiation dose calculations. MIRD Pamphlet No. 14, revised. J. Nucl. Med. 40, 102S–123S.

Thomas S.R. Stabin M.G. Castronovo F.P. , 2005. Radiation-absorbed dose from ²⁰¹Tl-thallous chloride. J. Nucl. Med. 46, 502–508.

Tobin R.E. Schneider P.B. , 1976. Uptake of ⁶⁷Ga in the lactating breast and its persistence in milk: case report. J. Nucl. Med. 17, 1055–1056.

Torizuka K. Yonekura Y. Nishimura T. , 1991. The phase 1 study of β-methyl-p-(¹²³I)-iodophenyl-pentadecanoic acid (¹²³I-BMIPP). Kagu Igaku 28, 681–690.

Towsen J.E.C. , 2002. Radiation dosimetry and protection in PET, in: Valk P.E. Bailey D.L. Townsend D.W. (Eds.), Positron Emission Tomography; Basic Science and Clinical Practice. Springer-Verlag, London, pp. 265–279.

Vallabhajosula S. Zimmerman R.E. Picard M. , 1989. Technetium-99m ECD: a new brain imaging agent: In vivo kinetics and biodistribution studies in normal human subjects. J. Nucl. Med. 30, 599–604.

Vanhavere F. Berus D. Buls N. , 2006. Use of extremity dose meters in a hospital environment. Radiat. Prot. Dosim. 118, 190–195.

Verhoeff N.P. Sokole E.B. Stabin M. , 1993. Dosimetry of iodine-123 iodobenzamide in healthy volunteers. Eur. J. Nucl. Med. 20, 747–752.

Verhoeff N.P. Busemann Sokole E. Hengst D. Stubbs J.B. van Royen E.A. , 1993. Dosimetry of iodine-123 iomazenil in humans. Eur. J. Nucl. Med. 20, 580–584.

Versijpt J. Dumont F. Thierens H. , 2000. Biodistribution and dosimetry of [¹²³I]iodo-PK 11195: a potential agent for SPET imaging of the peripheral benzodiazepine receptor. Eur. J. Nucl. Med. 27, 1326–1333.

Visseaux H. Vuillez J.P. Giraud J.Y. , 2007. Dosimetric study and radioprotection optimization in 18F-FDG scintigraphy. Medecine Nucleaire 28, 205–217.

Votaw J.R. Ansari M.S. Scott Mason N. , 1995. Dosimetry of iodine-123-epidepride: A dopamine D2 receptor ligand. J. Nucl. Med. 36, 1316–1321.

Volkow N.D. Ding Y.S. Fowler J.S. , 1995. A new PET ligand for the dopamine transporter: Studies in human brain. J. Nucl. Med. 36, 2162–2168.

Waterhouse R.N. Stabin M.G. Page J.G. , 2003. Preclinical acute toxicity studies and rodent-based dosimetry estimates of the novel sigma-1 receptor radiotracer [¹⁸F]FPS. Nucl. Med. Biol. 30, 555–563.

Watson E.E. Stabin M.G. Eckerman K.F. , 1989. A model of the peritoneal cavity for use in internal dosimetry. J. Nucl. Med. 30, 2002–2011.

Wester H.J. Herz M. Senkowitsch-Schmidtke R. Schwaiger M. Stöcklin G. Hamacher K. , 1999a. Preclinical evaluation of 4-[¹⁸F]fluoroprolines: diasteromeric effect on metabolism and uptake in mice. Nucl. Med. Biol. 26, 259–265.

Wester H.J. Herz M. Weber W. , 1999b. Synthesis and radiopharmacology of O-(2-[¹⁸F]fluoroethyl)-1-tyrosine for tumor imaging. J. Nucl. Med. 40, 205–212.

Westera G. Buck A. Burger C. Leenders K.L. von Schultness G.K. Schubiger A.P. , 1996. Carbon-11 and iodine-123 labelled iomazenil: A direct PET-SPECT comparison. Eur. J. Nucl. Med. 23, 5–12.

Whitby M. Martin C.J. , 2002. Options for shielding the hand during dispensing and administration of radiopharmaceuticals. Sixth European ALARA Network Workshop in Occupational Exposure Optimization in Medical Field and Radiopharmaceutical Industry, pp. 167–170 (http://www.eualara.net/images/stories/pdf/program6/Session%20C/M_Whithy.pdf).

Whitby M. Martin C.J. , 2003. Investigation using an advanced extremity gamma instrumentation system of options for shielding the hand during the preparation and injection of radiopharmaceuticals. J. Radiol. Prot. 23, 79–96.

Whitby M. Martin C.J. , 2005. A multi-centre study of dispensing methods and hand doses in hospital radiopharmacies. Nucl. Med. Commun. 26, 49–60.

van de Wiele C. De Vos F. De Sutter J. , 1999. Biokinetics and dosimetry of (iodine-123)-iodomethyl-N,N-dimethyltamoxifen, an (anti)oestrogen receptor radioligand. Eur. J. Nucl. Med. 26, 1259–1264.

Wilhelm A.J. Mijnhout G.S. Franssen E.J. , 1999. Radiopharmaceuticals in sentinel lymph-node detection - an overview. Eur. J. Nucl. Med. 26, S36–S42.

Williams E.D. Laird E.E. Forster E. , 1987. Monitoring radiation dose to the hands in nuclear medicine: Location of dosemeters. Nucl. Med. Commun. 8, 449–503.

Williams L.R. Leggett R.W. , 1989. Reference values for resting blood flow to organs of man. Clin. Phys. Physiol. Meas. 10, 187–217.

Wilson A.A. Inaba T. Fischer N. , 1998. Derivatives of WAY 100635 as potential imaging agents for 5-HT1A receptors: Syntheses, radiosyntheses, and in vitro and in vivo evaluation. Nucl. Med. Biol. 25, 769–776.

Winchell H.S. Horst W.D. Braun L. Oldendorf W.H. Hattner R. Parker H. , 1980. N-Isopropyl (¹²³I)p-iodoamphetamine: single-pass brain uptake and washout; binding to brain synaptosomes; and localisation in dog and monkey brain. J. Nucl. Med. 21, 947–952.

Wistow B.W. Subramanian G. Van Heertum R.L. , 1977. An evaluation on ^99mTc-labeled hepatobiliary agents. J. Nucl. Med. 18, 455–461.

Wrzesień M. Olszewski J. Jankowski J. , 2008. Hand exposure to ionising radiation of nuclear medicine workers. Rad. Prot. Dosim. 130, 325–330.

Wu R.K. Siegel J.A. Rattner Z. Malmud L.S. , 1984. Tc-99m HIDA dosimetry in patients with various hepatic disorders. J. Nucl. Med. 25, 905–912.

Yeh S.H. Liu R.S. Wu L.C. Yen S.H. Chang C.W. Chen K.Y. , 1999. ¹¹C-acetate clearance in nasopharyngeal carcinoma. Nucl. Med. Commun 20, 131–134.

Yoshizumi T. Nozaki S. Fukuchi K. , 2000. Pharamacokinetics and metabolism of ¹²³I-BMIPP fatty acid analog in healthy and CD36-deficient subjects. J. Nucl. Med. 41, 1134–1138.

Zanzonico P.B. , 2000. Internal radionuclide radiation dosimetry: A review of basic concepts and recent developments. J. Nucl. Med. 41, 297–308.

Zhu X. , 2004. Radiation safety considerations with yttrium-90 ibritumomab tiuxetan (Zevalin). Semin. Nucl. Med. 34, 20–23.